scholarly journals Early Rise in Serum Concentration of Transferrin Receptor Induced by Recombinant Human Erythropoietin in Very-Low-Birth-Weight Infants

1994 ◽  
Vol 36 ◽  
pp. 85-89 ◽  
Author(s):  
Sanna M Kivivuori ◽  
Markku Heikinheimo ◽  
Anna-Maija Teppo ◽  
Martti A Siimes
Keyword(s):  
Birth Weight ◽  
Low Birth Weight ◽  
Serum Concentration ◽  
Transferrin Receptor ◽  
Recombinant Human Erythropoietin ◽  
Very Low Birth Weight ◽  
Low Birth Weight Infants ◽  
Human Erythropoietin ◽  
Early Rise

Recombinant Human Erythropoietin Stimulates Erythropoiesis and Reduces Erythrocyte Transfusions in Very Low Birth Weight Preterm Infants

PEDIATRICS ◽  
1995 ◽  
Vol 95 (1) ◽  
pp. 1-8
Author(s):  
Kevin M. Shannon ◽  
Julian F. Keith ◽  
William C. Mentzer ◽  
Richard A. Ehrenkranz ◽  
Mark S. Brown ◽  
...  
Keyword(s):  
Placebo Group ◽  
Birth Weight ◽  
Low Birth Weight ◽  
Preterm Infants ◽  
Recombinant Human Erythropoietin ◽  
Very Low Birth Weight ◽  
Group Versus ◽  
Weekly Dose ◽  
Human Erythropoietin ◽  
Transfusion Requirements

Design and methods. We hypothesized that treatment with recombinant human erythropoietin (r-HuEPO) would stimulate erythropoiesis and would thereby reduce the need for erythrocyte transfusions in preterm infants. We treated 157 preterm infants born at 26.9 ± 1.6 weeks of gestation who weighed 924 ± 183 g at birth with either subcutaneous r-HuEPO (100 U/kg/d, 5 days per week) or placebo for 6 weeks in a randomized, double-blind, controlled clinical trial. All patients received oral iron and were managed according to uniform conservative transfusion guidelines. Results. Treatment with r-HuEPO was associated with fewer erythrocyte transfusions (1.1 ± 1.5 per infant in the r-HuEPO group versus 1.6 ± 1.7 per infant in the placebo group; P = .046) and with a reduction in the volume of packed erythrocytes transfused (16.5 ± 23.0 mL versus 23.9 ± 25.7 mL per infant; P = .023). Overall, 43% of the infants in the r-HuEPO group and 31% of placebo-treated infants were transfusion-free during the study (P = .18). The volume of blood removed for laboratory tests and the need for respiratory support at the start of treatment had major effects on transfusion requirements independent of r-HuEPO. Reticulocyte counts were higher during treatment in the r-HuEPO group (P = .0001), and r-HuEPO-treated infants had higher hematocrit values at the end of the study (32% versus 27.3% in the placebo group; P = .0001). We found no differences in the incidence of major complications of prematurity between the treatment groups. Conclusion. We conclude that treatment with r-HuEPO at a weekly dose of 500 U/kg stimulates erythropoiesis, moderates the course of anemia, is associated with a reduction in erythrocyte transfusions, and appears safe in very low birth weight preterm infants who are receiving iron supplements. Conservative transfusion criteria, minimization of phlebotomy losses, and treatment with r-HuEPO are complementary strategies to reduce erythrocyte transfusions in these infants.

Effect of short term recombinant human erythropoietin (rHuEPO) therapy in the prevention of anemia of prematurity (AOP) in very low birth weight (VLBW) neonates

2013 ◽  
Vol 38 (3) ◽  
pp. 119-123 ◽  
Author(s):  
BHN Yasmeen ◽  
MAKA Chowdhury ◽  
MM Hoque ◽  
MM Hossain ◽  
R Jahan ◽  
...  
Keyword(s):  
Folic Acid ◽  
Birth Weight ◽  
Low Birth Weight ◽  
Recombinant Human Erythropoietin ◽  
Very Low Birth Weight ◽  
Controlled Trial ◽  
Control Group ◽  
Short Term ◽  
Human Erythropoietin ◽  
Anaemia Of Prematurity

Premature infants especially those with birth weight <1500 g suffer from Anaemia of prematurity (AOP) and associated problems. Erythropoietin therapy is a safe effective way to prevent and to treat anaemia of prematurity. To evaluate the effect of short term administration of recombinant human erythropoietin (rHuEPO) with iron and folic acid in very low birth weight (VLBW) neonates in the prevention of anaemia of prematurity. A randomized controlled trial was carried out at Dhaka Shishu Hospital. Sixty preterm very low birth weight (PTVLBW) babies were enrolled in this study. Thirty were assigned to rHuEPO group and 30 as control. Baseline haematologic values were estimated before administration of rHuEPO. From day 7 of life rHuEPO-200 IU/kg/dose subcutaneously every alternate day for 2 weeks was administered to rHuEPO group. All infants in both groups have received oral iron, folic acid from day 14. Clinical and haematological assessment was done at 6 and 10 weeks of life. Baseline clinical characteristics and haematologic values were almost similar in both groups. This study has shown increase in haematological values(haemoglobin and haematocrit) and reduction in the number of blood transfusions during both the 1st and 2nd follow up in rHuEPO group in comparison to control group (p<0.01). Short term rHuEPO appears to be very effective in prevention of Anaemia of prematurity. DOI: http://dx.doi.org/10.3329/bmrcb.v38i3.14340 Bangladesh Med Res Counc Bull 2012; 38(3): 119-123 (December)

scholarly journals The effectiveness of umbilical cord milking/ delayed cord clamping and recombinant human erythropoietin in reducing red blood cell transfusions in extremely and very low birth weight infants

2021 ◽  
Vol 20 (3) ◽  
pp. 36-45
Author(s):  
D. R. Sharafutdinova ◽  
E. N. Balashova ◽  
А. R. Kirtbaya ◽  
A. Yu. Ryndin ◽  
J. M. Golubtsova ◽  
...  
Keyword(s):  
Birth Weight ◽  
Low Birth Weight ◽  
Umbilical Cord ◽  
Very Low Birth Weight ◽  
Delayed Cord Clamping ◽  
Low Birth Weight Infants ◽  
Human Erythropoietin ◽  
Cord Clamping ◽  
Red Blood Cell Transfusions ◽  
Umbilical Cord Milking

Anemia of prematurity is one of the most common and serious problems of neonatology. The main focus is to prevent of anemia in preterm infants. The aim of the study was to assess effectiveness of umbilical cord milking/delayed cord clamping and erythropoietin therapy in reducing red blood cell transfusions in extremely and very low birth weight infants. This clinical study was approved by the Commission on ethics of biomedical research (Protocol No. 12 November 17, 2016) and approved by the Scientific Council of National Medical Research Center for obstetrics, gynecology and perinatology named academician V.I. Kulakov of the ministry of Healthcare of the Russian Federation (Protocol No. 19 of November 29, 2016). Analysis of 482 extremely and very low birth weight infants was conducted (from 2008 to 2018). Umbilical cord milking or delayed umbilical cord clamping, both, and in combination with recombinant human erythropoietin therapy, decreasing the phlebotomy losses significantly reduces the need for transfusions of red blood cells in extremely and very low birth weight infants. The effectiveness of erythropoietin therapy, time of its start and various treatment schemes remain controversial, therefore further researches are necessary.

Enhancement of erythropoiesis by recombinant human erythropoietin in low birth weight infants: A pilot study

1992 ◽  
Vol 120 (4) ◽  
pp. 586-592 ◽  
Author(s):  
Kevin M. Shannon ◽  
William C. Mentzer ◽  
Robert I. Abels ◽  
Marcia Wertz ◽  
Jodie Thayer-Moriyama ◽  
...  
Keyword(s):  
Birth Weight ◽  
Pilot Study ◽  
Low Birth Weight ◽  
Recombinant Human Erythropoietin ◽  
Low Birth Weight Infants ◽  
Human Erythropoietin
Sign in / Sign up

Export Citation Format

Share Document